Form 8-K

8-K — NEUROONE MEDICAL TECHNOLOGIES Corp

Accession: 0001213900-26-039992

Filed: 2026-04-03

Period: 2026-04-03

CIK: 0001500198

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Submission of Matters to a Vote of Security Holders

Item: Financial Statements and Exhibits

Documents

8-K — ea0285085-8k_neuroone.htm (Primary)

EX-10.1 — FIRST AMENDMENT TO NEUROONE MEDICAL TECHNOLOGIES CORPORATION 2025 EQUITY INCENTIVE PLAN (ea028508501ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0285085-8k_neuroone.htm · Sequence: 1

false

0001500198

2026-04-03

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

April 3, 2026

NeuroOne Medical Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-40439

27-0863354

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

7599 Anagram Dr., Eden Prairie, MN 55344

(Address of principal executive offices and zip

code)

952-426-1383

(Registrant’s telephone number including

area code)

(Registrant’s former name or former address,

if changed since last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.001 per share

NMTC

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers;

Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 25, 2026, the

Board of Directors (the “Board”) of NeuroOne Medical Technologies Corporation (the “Company”) adopted a First

Amendment (the “Amendment”) to the NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan (the “2025 Equity

Incentive Plan”). On April 3, 2026, at the Annual Meeting (as defined below), the stockholders of the Company approved the Amendment.

Pursuant to the terms and

conditions of the Amendment, the 2025 Equity Incentive Plan was amended to:

● increase the aggregate number of shares of Common Stock that

may be issued under the 2022 Equity Incentive Plan by 1,500,000 new shares; and

● automatically increase on January 1st of each year for a period

of five years commencing on January 1, 2027 and ending on (and including) January 1, 2031, the aggregate number of shares of Common Stock

that may be issued pursuant to Awards (as defined in the 2025 Equity Incentive Plan) by an amount equal to 5% of the Fully Diluted Shares

(as defined in the 2025 Equity Incentive Plan) as of the last day of the preceding calendar year, provided, however that the Board may

act prior to the effective date of any such annual increase to provide that the increase for such year will be a lesser number of shares

of Common Stock.

A copy of the Amendment to

the 2025 Equity Incentive Plan is included as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security

Holders.

At the annual meeting (the

“Annual Meeting”) of stockholders of the Company on April 3, 2026,

stockholders (i) elected two Class III directors to the Company’s Board of Directors, each to serve a three-year term until

the 2029 annual meeting of stockholders, (ii) ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered

public accounting firm for the fiscal year ending September 30, 2026, (iii) approved an amendment to the Company’s Certificate

of Incorporation to effect a reverse stock split of the Company’s outstanding common stock at a ratio in the range of 1-for-2 to

1-for-15 to be determined by the Company’s Board of Directors, (iv) approved an amendment to the NeuroOne Medical Technologies Corporation

2025 Equity Incentive Plan, and (v) authorized one or more adjournments of the Annual Meeting to solicit additional proxies in the event

there are insufficient votes to approve Proposal 3. Proposals are described in detail in the Company’s definitive proxy statement

filed with the Securities and Exchange Commission on March 9, 2026.

A total of 30,272,834 shares

of the Company’s common stock were present at the meeting in person or by proxy, which represents approximately 59.72% of the shares

of common stock outstanding as of the record date for the Annual Meeting.

The results of the voting are shown below:

Proposal 1—Election of Directors

Class III Nominees

Votes For

Votes

Withheld

Broker Non-

Votes

Jeffrey Mathiesen

18,384,823

494,745

11,393,266

Edward Andrle

18,174,404

705,164

11,393,266

Proposal 2—Ratification of Appointment of Independent Registered

Public Accounting Firm

Votes For

Votes Against

Votes Abstain

30,031,054

70,706

171,074

Proposal 3—Approval of an Amendment to the Company’s

Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock at a ratio in the range of

1-for-2 to 1-for-15, to be determined at the discretion of the Company’s Board of Directors

Votes For

Votes Against

Votes Abstain

28,408,499

1,780,031

84,304

Proposal 4—Approval of an Amendment to the NeuroOne

Medical Technologies Corporation 2025 Equity Incentive Plan

Votes For

Votes Against

Votes Abstain

Broker Non-Votes

15,146,194

3,415,319

318,056

11,393,265

Proposal 5—Authorization of One or More Adjournments

of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 3

Votes For

Votes Against

Votes Abstain

29,020,938

1,067,842

184,052

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

10.1

First Amendment to NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan.

104

Cover Page Interactive Data File (embedded with Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,

the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEUROONE MEDICAL TECHNOLOGIES CORPORATION

Dated: April 3, 2026

By:

/s/ David Rosa

David Rosa

Chief Executive Officer

EX-10.1 — FIRST AMENDMENT TO NEUROONE MEDICAL TECHNOLOGIES CORPORATION 2025 EQUITY INCENTIVE PLAN

EX-10.1

Filename: ea028508501ex10-1.htm · Sequence: 2

Exhibit 10.1

FIRST AMENDMENT TO

NEUROONE MEDICAL TECHNOLOGIES

CORPORATION

2025 EQUITY INCENTIVE

PLAN

RECITALS

A. NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”) sponsors

the NeuroOne Medical Technologies, Inc. 2025 Equity Incentive Plan (the “Plan”).

B. The Plan is amended by this Amendment 1 (this “First Amendment”)

in the following respects, effective from and after the date this First Amendment is approved by the stockholders of NeuroOne Medical

Technologies Corporation, in accordance with the Plan. Following such effective date, any reference to the “Plan” shall mean

the Plan, as amended by this First Amendment. All capitalized terms used but not otherwise defined herein shall have the respective meanings

ascribed to such terms in the Plan.

AMENDMENT

1. Section 2(a) of the

Plan is hereby deleted in its entirety and replaced with the following:

“Share Reserve.

Subject to adjustment in accordance with Section 2(c) and any adjustments as necessary to implement any Capitalization Adjustments, the

aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed the sum of: (i) 4,500,000 new shares,

plus (ii) the number of Returning Shares, if any, as such shares become available from time to time. In addition, subject to any adjustments

as necessary to implement any Capitalization Adjustments, such aggregate number of shares of Common Stock will automatically increase

on January 1st of each year for a period of five years commencing on January 1, 2027 and ending on (and including) January 1, 2031, by

an amount equal to 5% of the Fully Diluted Shares as of the last day of the preceding calendar year; provided, however that the Board

may act prior to the effective date of any such annual increase to provide that the increase for such year will be a lesser number of

shares of Common Stock.”

Except as set forth in this amendment, the Plan shall be unaffected hereby and shall remain in full force and effect.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Apr. 03, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 03, 2026

Entity File Number

001-40439

Entity Registrant Name

NeuroOne Medical Technologies Corporation

Entity Central Index Key

0001500198

Entity Tax Identification Number

27-0863354

Entity Incorporation, State or Country Code

Entity Address, Address Line One

7599 Anagram Dr.

Entity Address, City or Town

Eden Prairie

Entity Address, State or Province

Entity Address, Postal Zip Code

55344

City Area Code

952

Local Phone Number

426-1383

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

NMTC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration